Loading…
Tenaya Therapeutics, Inc. is projected to rise to $1.05 by 2027, a +24% move from its current price of $0.85. TNYA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.8186 | $0.8499 | $0.8824 | -0.01% |
| Jul 14 | $0.8059 | $0.8498 | $0.8962 | -0.02% |
| Jul 15 | $0.7963 | $0.8498 | $0.9068 | -0.03% |
| Jul 16 | $0.7882 | $0.8497 | $0.9159 | -0.04% |
| Jul 17 | $0.7812 | $0.8496 | $0.924 | -0.05% |
| Jul 18 | $0.7749 | $0.8495 | $0.9313 | -0.06% |
| Jul 19 | $0.7691 | $0.8494 | $0.9381 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7691 | $0.8494 | $0.9381 | -0.07% |
| Week 2 | $0.7376 | $0.8488 | $0.9769 | -0.14% |
| Week 3 | $0.7142 | $0.8483 | $1.01 | -0.20% |
| Week 4 | $0.695 | $0.8477 | $1.03 | -0.27% |
| Week 5 | $0.6784 | $0.8471 | $1.06 | -0.34% |
| Week 6 | $0.6637 | $0.8465 | $1.08 | -0.41% |
| Week 7 | $0.6505 | $0.846 | $1.10 | -0.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops, and delivers therapies for heart disease in the United States.
Its lead product candidates include TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.
It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Tenaya Therapeutics, Inc. (TNYA) currently trades at $0.8654 per share and has a market cap of $187.79M. It is ranked 3818 by market capitalization.
The stock operates within the Healthcare sector. The price outlook, according to the forecast, shows a path of upside from 2027 onward, with a series of year-by-year averages and bullish sentiment emerging in the longer horizon.
Forecasts span from 2026 through 2050, starting with a 2026 avg of $0.8654 and rising to 2050 avg of $7.17, with the annual ROIs ranging from 0 in 2026 to 728.2 in 2050 and sentiment skewed toward BULLISH across the longer horizon.
A major floor 35.3% below — a decisive break under it would weaken the trend.
The nearest floor, 20.0% below — buyers have tended to step in here.
The nearest ceiling, 8.2% above — a clean break opens room to run.
A major ceiling 25.1% above — clearing it would confirm fresh momentum.
Key TNYA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TNYA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.877 | Sell | $0.8561 | Sell |
| MA 10 | $0.811 | Buy | $0.8251 | Buy |
| MA 20 | $0.7626 | Buy | $0.7943 | Buy |
| MA 50 | $0.7893 | Buy | $0.7783 | Buy |
| MA 100 | $0.7534 | Buy | $0.7974 | Buy |
| MA 200 | $0.9715 | Sell | $0.8924 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.14 | Neutral |
| Stoch RSI (14) | 66.01 | Neutral |
| CCI (20) | 120.05 | Buy |
| Williams %R (14) | -22.73 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 19.83 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 77.27 | Neutral |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | 0.11 | Buy |
| Ultimate (7,14,28) | 69.01 | Neutral |
| Momentum (10) | 0.16 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 0.91 | Sell |
| ADX (14) | 15.63 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is bullish, with RSI14 at 70.
SMA50 is $0.7738 and SMA200 is $0.9807, placing near-term technicals between key moving averages. Support is reported at $0.68 and resistance at $0.87, configuring a tight trading range near the current price.
The 30-day price range runs from $0.6727 to $1.11, and the stock shows an annualized volatility of 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.55 | $0.85 | $1.08 | 0% | Neutral | |
| $0.8079 | $1.05 | $1.46 | +24% | Bullish | |
| $0.8093 | $1.10 | $1.60 | +29% | Bullish | |
| $0.7998 | $1.12 | $1.70 | +32% | Bullish | |
| $0.9806 | $1.42 | $2.21 | +67% | Bullish | |
| $1.17 | $1.73 | $2.78 | +104% | Bullish | |
| $1.45 | $2.21 | $3.64 | +160% | Bullish | |
| $1.59 | $2.48 | $4.18 | +192% | Bullish | |
| $1.45 | $2.32 | $3.98 | +173% | Bullish | |
| $1.63 | $2.66 | $4.65 | +213% | Bullish | |
| $2.54 | $4.60 | $8.69 | +442% | Bullish | |
| $3.97 | $8.71 | $18.34 | +924% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.55 | $0.85 | $1.00 | +0.00% |
| August 2026 | $0.6874 | $0.8198 | $1.01 | -3.56% |
| September 2026 | $0.6996 | $0.8425 | $1.05 | +2.78% |
| October 2026 | $0.6904 | $0.8384 | $1.06 | -0.49% |
| November 2026 | $0.6638 | $0.8118 | $1.04 | -3.17% |
| December 2026 | $0.6788 | $0.8357 | $1.08 | +2.94% |
Click any year to see its month-by-month TNYA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Tenaya Therapeutics, Inc.'s 2026 outlook centres on $0.85, within a $0.55 to $1.08 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, TNYA could reach as high as $1.46, with a base case around $1.05 and support toward $0.8079 — roughly +24% from $0.85. Momentum favours further upside here.
Expect TNYA to range from $0.8093 to $1.60 through 2028. The $1.10 average target implies a +29% move from current prices. That is up +4% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The TNYA price prediction for 2029 points to an average of $1.12 (low $0.7998, high $1.70) — a potential gain of +32% on today's $0.85. Momentum favours further upside here.
In 2030, TNYA is projected to trade between $0.9806 and $2.21, averaging $1.42 — a potential gain of +67% from today's $0.85. That is up +26% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Tenaya Therapeutics, Inc.'s 2031 outlook centres on $1.73, within a $1.17 to $2.78 range. That is up +22% on the projected 2030 average. That marks a +104% change versus current levels. Momentum favours further upside here.
By 2032, TNYA could reach as high as $3.64, with a base case around $2.21 and support toward $1.45 — roughly +160% from $0.85. Buyers look set to stay in control over this stretch.
Expect TNYA to range from $1.59 to $4.18 through 2033. The $2.48 average target implies a +192% move from current prices. That is up +12% on the projected 2032 average. Momentum favours further upside here.
The TNYA price prediction for 2034 points to an average of $2.32 (low $1.45, high $3.98) — a potential gain of +173% on today's $0.85. Buyers look set to stay in control over this stretch.
In 2035, TNYA is projected to trade between $1.63 and $4.65, averaging $2.66 — a potential gain of +213% from today's $0.85. That is up +14% on the projected 2034 average. Momentum favours further upside here.
Tenaya Therapeutics, Inc.'s 2040 outlook centres on $4.60, within a $2.54 to $8.69 range. That is up +73% on the projected 2035 average. That marks a +442% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, TNYA could reach as high as $18.34, with a base case around $8.71 and support toward $3.97 — roughly +924% from $0.85. Momentum favours further upside here.
Investing $1,000 in TNYA today (≈ 1,176.470588 TNYA) could be worth
$10,244.59
+$9,244.59 (+924%) by 2050 · US Dollar
Based on the average projected TNYA price of $8.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TNYAwould be worth at today's price.
$1,000 invested in TNYA on Jul 10, 2025 (≈ 1,453.488323 TNYA) would be worth
$1,235.47
+$235.47 (+23.5%) today · 1.24× · US Dollar
Based on a TNYA entry price of $0.688 vs. today's $0.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.787 | $1,080.05 | +8.0% |
| 1 month ago | $0.698 | $1,217.77 | +21.8% |
| 3 months ago | $0.69 | $1,231.88 | +23.2% |
| 6 months ago | $0.737 | $1,153.32 | +15.3% |
| 1 year ago | $0.688 | $1,235.47 | +23.5% |
| All time (4.9y) ago | $15.35 | $55.37 | -94.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TNYA forecast.
Our base-case forecast reaches $1.70 around 2031.
Implied market cap at $1.70: $368.9M
The multi-year forecast shows a clear long-run upside with a rising average price and substantial ROIs in the later years.
In 2026 the min is $0.55, the avg is $0.8654, and the max is $1.10, with an ROI of 0 and a NEUTRAL sentiment.
For 2027 the min is $0.7988, the avg is $1.04, and the max is $1.46, with an ROI of 20.5 and a BULLISH sentiment. For 2028 the min is $0.7817, the avg is $1.06, and the max is $1.56, with an ROI of 22.8 and a BULLISH sentiment. For 2029 the min is $0.7615, the avg is $1.07, and the max is $1.63, with an ROI of 23.8 and a BULLISH sentiment.
In 2030 the min is $0.9078, the avg is $1.32, and the max is $2.07, with an ROI of 52.1 and a BULLISH sentiment. In 2031 the min is $1.06, the avg is $1.58, and the max is $2.55, with an ROI of 82.6 and a BULLISH sentiment. In 2032 the min is $1.32, the avg is $2.02, and the max is $3.35, with an ROI of 133.6 and a BULLISH sentiment.
In 2033 the min is $1.43, the avg is $2.24, and the max is $3.79, with an ROI of 159 and a BULLISH sentiment. In 2034 the min is $1.29, the avg is $2.07, and the max is $3.58, with an ROI of 139.7 and a BULLISH sentiment. In 2035 the min is $1.44, the avg is $2.37, and the max is $4.17, with an ROI of 174.1 and a BULLISH sentiment.
In 2040 the min is $2.14, the avg is $3.93, and the max is $7.47, with an ROI of 354.1 and a BULLISH sentiment. In 2050 the min is $3.23, the avg is $7.17, and the max is $15.22, with an ROI of 728.2 and a BULLISH sentiment. These figures are estimates and illustrate potential trajectories rather than guarantees.
Tap a question to reveal the answer.
2030 avg $1.32, min $0.9078, max $2.07; ROI 52.1; sentiment BULLISH.
Forecast shows bullish sentiment in multiple years and rising averages, including 2027 avg $1.04, 2030 avg $1.32, 2040 avg $3.93, and 2050 avg $7.17, with ROIs up to 728.2. These are estimates, not guarantees.
Yes. 2032 avg $2.02; 2033 avg $2.24; 2034 avg $2.07; 2035 avg $2.37; 2050 avg $7.17.
$0.8654 per share.
Sentiment BULLISH; RSI14 70; SMA50 $0.7738; SMA200 $0.9807; support $0.68; resistance $0.87; thirtyDayRange low $0.6727, high $1.11; annualized volatility 70%.
Tenaya Therapeutics, Inc. Community Discussion
0Share your Tenaya Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.